The struggling psychedelics firm abandoned direct patient care in favor of developing tech for insurance reimbursement and ...

The firm's tried to shore up its position as the FDA and Health Canada cleared Phase II trials for its flagship psilocybin ...

The delay is at least the second such move by the USDA, the agency said in a press release, after it made a similar decision ...

The biotech reported progress on its lead molecule and out-licensed two candidates, amid cash constraints and a potential ...

A new credit facility provided $8 million in net proceeds for growth initiatives ahead of a planned mid-2025 integration with ...

The Toronto-based drugmaker's revenue held steady, helped by stronger performance from its Colombian operations.

While broader real estate stocks rallied on the Federal Reserve’s latest rate cut, with the Real Estate Select Sector SPDR ...

Regulators outlined recommendations and rules related to creating a safe working environment for those working with cannabis.

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...

During the third quarter, 4Front retained Canaccord Genuity Corp. to help with an internal reorganization, particularly ...

Ditching cannabis growing tech for hemp-based drinks marks a new era for the firm under its new GTI leadership.

Tilt also reported a net loss of $12.6 million in the quarter versus a net loss of $8.7 million in the prior year period. At ...